In frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS), recent studies have presumed relationships between cognitive declines and striatal dysfunctions. The striatum contributes to socio-cognitive functions by receiving glutamatergic inputs from the cerebral cortices. However, the vulnerability of these cortico-striatal inputs is unclear in these diseases. This study aimed to evaluate the glutamatergic inputs to the striatum from the cerebral cortices in patients with sporadic TDP-43-related FTLD (FTLD-TDP) and ALS (ALS-TDP). We examined 46 consecutively autopsied patients (31 FTLD-TDP and 15 ALS patients) and 10 normal controls. The axon terminals of the glutamatergic cortico-striatal projection neurons were quantified at the striatum using antivesicular glutamate transporter-1 (VGLUT-1) immunohistochemistry. In results, all FTLD-TDP patients displayed marked depletion of VGLUT-1-positive axon terminals in the caudate head and putamen. Particularly, the patients with type C pathology showed a severe loss. The nondemented ALS patients displayed loss of VGLUT-1-positive axon terminals in the putamen, but those were relatively spared in the caudate head. Confocal microscopy revealed TDP-43 aggregations within VGLUT-1-positive axon terminals in a subset of the patients. Our results indicate marked involvement of glutamatergic striatal inputs from the cerebral cortices in association with sociocognitive declines in a disease spectrum of TDP-43 proteinopathy.
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is a pathologic entity of sporadic and familial neurodegenerative diseases that is clinically characterized by frontotemporal dementia (FTD) syndrome. The prominent manifestations of FTD are various socio-cognitive declines, including behavioral variant FTD (bvFTD) and language disorders (1) (2) (3) . Neuronal and glial inclusions of pathologic proteins, including TAR DNA-binding protein 43 kDa (TDP-43), 3-or 4-repeat tau, and fused-insarcoma, are known pathologic features of FTLD (4) (5) . In particular, TDP-43-related FTLD (FTLD-TDP) is a predominant pathologic background that accounts for approximately half of the total number of FTLD patients (5) . Currently, the cortical TDP-43 pathology is morphologically classified to type A, B, C, and D (6). FTLD-TDP type A is defined as the presence of neuronal cytoplasmic inclusions and short dystrophic neurites that are predominantly located in layer 2 of the neocortex; type B is defined as a predominance of neuronal cytoplasmic inclusions in all cortical layers; type C is defined as a predominance of long dystrophic neurites in layer 2 and cytoplasmic inclusions in the dentate granular cells of the hippocampus; and type D is defined as a predominance of short dystrophic neurites and neuronal intranuclear inclusions in association with valosincontaining protein gene mutations. TDP-43 is also the major pathologic protein observed in sporadic amyotrophic lateral sclerosis (ALS-TDP) (4) . In some cases, ALS-TDP and FTLD-TDP are clinically concurrent, a condition known as FTD with motor neuron disease (FTD-MND), or ALS with dementia (7, 8) . From the perspective of "TDP-43 proteinopathy", FTLD-TDP and ALS-TDP are considered to represent a continuous disease spectrum (7, 8) .
Recently, clinical and pathologic investigations have presumed a relationship between dysfunction of the striatum and socio-cognitive declines in patients with FTLD-TDP or ALS-TDP (9) (10) (11) (12) (13) (14) (15) . The striatum plays important roles in behavior, execution, and language generation, receiving neural inputs from the cerebral cortices (16) (17) (18) . Importantly, the glutamatergic excitatory projections to the striatum from the orbitofrontal/prefrontal cortices are critical to these sociocognitive functions (19) (20) (21) . However, there have been no pathologic observations concerning the vulnerability of the glutamatergic inputs to the striatum from the cortices in FTLD-TDP and ALS-TDP patients.
This study aimed to evaluate the glutamatergic corticostriatal inputs in autopsied patients with sporadic FTLD-TDP and ALS-TDP. Our strategy for the pathologic evaluation was to perform immunohistochemical observations of vesicular glutamate transporter-1 (VGLUT-1)-positive axon terminals in the caudate head and putamen. In the striatum, anti-VGLUT-1 immunohistochemistry specifically labels the glutamatergic axon terminals of cortico-striatal projection neurons and does not label those of other cell origins (22) (23) (24) . Therefore, this method is appropriate for directly observing the glutamatergic inputs to the striatum from the cortices. We analyzed 31 patients with sporadic FTLD-TDP and 15 patients with sporadic ALS-TDP, who were consecutively autopsied.
MATERIALS AND METHODS

Study Subjects
Initially, we enrolled 58 sporadic, adult-onset FTLD-TDP patients who were consecutively autopsied from January 1989 to December 2015. We also enrolled 21 patients with sporadic ALS-TDP who were consecutively autopsied from January 2013 to December 2015. The autopsies and pathologic diagnoses were performed at the Department of Neuropathology in the Institute for Medical Science of Aging at Aichi Medical University. FTLD-TDP was pathologically diagnosed according to previously established criteria (6, 25) . ALS-TDP was diagnosed pathologically according to the observed patterns of neuronal loss, gliosis, and neuronal TDP-43 aggregations in both the upper and lower motor neuron systems (8) . From the enrolled patients, we excluded those who fulfilled the diagnostic criteria for other neurologic disorders, including either intermediate or high-grade Alzheimer disease (AD) according to the 2012 neuropathologic guidelines for AD, dementia with Lewy bodies (DLB) in either the limbic or neocortical stage, argyrophilic grain disease (AGD) at stage I or above, as defined by Saito et al., cerebral amyloid angiopathy with an Olichney score higher than 1, or cerebrovascular disease involving the cerebral cortices or subcortical gray matter regions (26) (27) (28) (29) . In addition, patients who had received a respirator/tracheotomy or showed anoxic changes in their brain tissue were excluded.
As normal controls, we included 10 normal, agematched control subjects (4 females and 6 males with a mean age at death of 69.4 years, SD, 8.5 years). Permission to perform an autopsy and to archive tissue samples for research purposes was obtained from family members after death, in accordance with ethical approval of the research project (Ethics Committee, Nagoya University, and Aichi Medical University, Aichi, Japan).
Subclassification of Study Subjects
Based on the clinical and pathologic findings, we classified the patients into FTD, FTD-MND, and ALS groups. The FTD group included patients who clinically presented FTD symptoms without ALS symptoms and exhibited pathologic findings of FTLD-TDP. The FTD-MND group included patients who clinically presented combined FTD and ALS symptoms and exhibited combined pathologic findings of FTLD-TDP and ALS-TDP. The other nondemented patients with ALS-TDP pathology were categorized into the ALS group. We compared the clinicopathologic findings among the FTD, FTD-MND, and ALS groups.
FTD symptoms, including bvFTD and language disorders, were identified using published diagnostic criteria (2, 3) . The motor symptoms/signs of ALS were defined as "possible" or higher categories according to the revised El Escorial criteria (30) . All patients had been clinically evaluated by neurologic specialists from the affiliated hospitals of Nagoya University. The clinical data for the enrolled patients were retrospectively obtained from case notes that were recorded at diagnosis and at an advanced stage of the illness.
Tissue Preparation
The tissues were fixed in 10% neutral-buffered formalin. The median duration of formalin-fixation was 20 days, ranging from 14 to 52 days. The median of postmortem delay to autopsies was 6 hours, ranging from 3 to 18 hours. The left hemisphere was initially cut 5 mm posterior to the mammillary bodies, and 8-mm-thick coronal sections were obtained using a slicer, followed by paraffin embedding. The striatum was evaluated in the sections where the caudate head, putamen, and globus pallidus were present (31) . Serial 5-lm-thick sections were stained using the hematoxylin and eosin, Klü-ver-Barrera, Bodian, and Gallyas-Braak methods. For routine immunohistochemical analyses, the following primary antibodies were used: NeuN (rabbit polyclonal, 1:500; Abcam, Cambridge, MA), antiubiquitin (mouse monoclonal, 1:250; Millipore, Billerica, MA), antiTDP-43 (TARDBP, rabbit polyclonal, 1:2500; ProteinTech, Chicago, IL), antiphosphorylated TDP-43 (pTDP-43 ser409/410, rabbit polyclonal, 1:5000; Cosmobio, Tokyo, Japan), antiglial fibrillary acidic protein (GFAP, rabbit polyclonal, 1:1000; Dako, Glostrup, Denmark), antiphosphorylated tau (AT-8, mouse monoclonal, 1:3000; Innogenetics, Gent, Belgium), antibeta-amyloid (beta-amyloid 6F/3D, mouse monoclonal, 1:100; Dako), antiphosphorylated alpha-synuclein (pSyn#64, mouse monoclonal, 1:1000; Wako, Osaka, Japan), antip62 N-terminal (P62N, guinea pig polyclonal, 1:100; PROGEN, Heidelberg, Germany), and antiubiquilin-2 (5F5, mouse monoclonal, 1:5000; Abnova, Taipei, Taiwan). Secondary immunolabeling was performed using a standard peroxidase method with the EnVision-kit (Dako). Diaminobenzidine (Wako, Japan) was used as a brown chromogen.
Immunohistochemical Evaluations of Axon Terminals
The axon terminals of the glutamatergic cortico-striatal projection neurons were labeled with an antiVGLUT-1 antibody (mouse, monoclonal, 1:500, Abnova) in the striatum. The striatum may mainly contain the axon terminals of excitatory or inhibitory corticofugal neurons, thalamic neurons, and striatal interneurons. However, in the striatum, only the axon terminals of excitatory, glutamatergic cortico-striatal projection neurons express VGLUT-1, and those of other origins do not (21-23). An antisynaptophysin antibody (rabbit polyclonal, 1:100, Dako) was used to recognize whole axon terminals within the striatum.
Double Immunofluorescence
To determine whether pTDP-43 was aggregated in the VGLUT-1-positive axon terminals, we performed doubleimmunofluorescence analysis of pTDP-43 and VGLUT-1 (n ¼ 3 from the FTD group, n ¼ 3 from the FTD-MND group, and n ¼ 3 from the ALS group). We also evaluated the localization of pTDP-43 and calcineurin (mouse monoclonal, 1:500, Sigma Aldrich). Calcineurin has been established as a reliable marker for GABA-ergic, striatal medium spiny neurons that recognizes the cell cytoplasm and neurites (32, 33) . The secondary antibodies used for immunofluorescence were antimouse IgG (Alexa Fluor 488; Molecular Probes, Carlsbad, CA) and antirabbit IgG (Alexa Fluor 561). The immunofluorescently labeled specimens were observed via laser confocal microscopy (LSM 710, Carl Zeiss, Gottingen, Germany). The settings of image acquisitions were as follows; master gains: 754 for VGLUT-1, 735 for calcineurin, and 971 for pTDP-43; digital gains: 1.23 for VGLUT-1 and calcineurin, and 1.24 for pTDP-43; digital offsets: À5.0 for calcineurin, and 0.0 for VGLUT-1 and pTDP-43; and pinholes: 80 mm for VGLUT-1, 50 mm for calcineurin, and 72 mm for pTDP-43. All specimens were observed under these settings at magnifications of Â630 (Plan-Apochromat Â63/1.40 Oil DIC M27, Carl Zeiss).
Quantitative Evaluation of Densities of Axon Terminals
To analyze densities of immunopositive axon terminals, we quantified % areas of immunostaining of VGLUT-1 or synaptophysin, which were calculated as (an area of immunopositivity/an area of a visual field) (Supplementary Data Fig. S1 ). The calculation was carried out by author Y.R. who was blinded to the patients' profiles, using the color-deconvolution plug-in of Image J software (NIH, Bethesda, MD) (34, 35) . Microscopic photographs of the caudate head and putamen, which were obtained from 10 visual fields (Â40 objectives, 36 000 lm 2 ) without any pencil fibers or vessels, were prepared for each patient. We took the photographs with focusing on the neuronal nucleoli; we quantified the immunopositive axon terminals within the focus depth. The software automatically acquired DAB-intensities from immunostained specimens and omitted the other chromogen and background staining out of the focus depth. The generated images were binarized, and % areas were calculated. Ultimately, averages of % areas from 10 visual fields were proven. Two of the authors (Y.R., M.Y.) independently performed this protocol using 10 normal controls, and interrater error was calculated (SPSS 21.0 software program, IBM). Intraclass correlation coefficients were 0.794 (p ¼ 0.009), and thus we concluded this protocol to be reliable.
Immunohistochemical Screen for the Hexanucleotide Repeat Expansion Sequence on Chromosome 9, Open-Reading Frame 72 (C9ORF72)
Our study excluded patients with a family history of any neurodegenerative disease. However, C9ORF72 hexanucleotide expansion-related FTLD/ALS often exhibits TDP-43 pathology and shows low penetration in some cases, although this mutation is extremely rare in the Japanese population (36, 37) . Ubiquilin and p-62 pathology in FTLD has been reported to correlate well with C9ORF72 hexanucleotide expansions (38, 39) . Because genetic material was not available for many of our patients, we screened all patients via immunohistochemistry analysis with antibodies against ubiquilin-2 and p-62 (8, 31) . None of the patients exhibited thick ubiquilin-2-or p62N-positive aggregations in the cerebellum or temporal gyrus, as is found in patients with a C9ORF72 expansion; therefore, our patients were presumed not to carry this mutation.
Statistical Analyses
The clinical and pathologic findings were compared using either the Mann-Whitney U test for quantitative variables or Pearson's chi-squared test to assess bivariate correlations. The Kruskal-Wallis test was employed to detect any significant differences in the 3 or 4 sample groups. The significance level was set at a p value of 0.05 for comparisons between 2 groups, at a p value of 0.016 for comparisons among 3 groups, and at a p value of 0.012 for comparisons among 4 groups. All statistical tests were two-sided and were performed using the SPSS 21.0 software program (IBM).
Regression Analyses
We performed regression analyses to evaluate effects of clinicopathological parameters on striatal VGLUT-1 densities. The subjected parameters included ages of death, sex, clinical durations, clinical subgroups (FTD, FTD-MND, and nondemented ALS), subtypes of dementia (bvFTD, PNFA, and SD), subtypes of FTLD-TDP pathology (type A, B, and C), formalin fixation times, and postmortem delay to autopsies.
RESULTS
Clinical Findings
From the 58 enrolled patients with pathologically confirmed FTLD-TDP, 31 patients were included in this study (8 with type A, 17 with type B, and 6 with type C. None of our patients were categorized as type D). The remaining 27 patients were excluded because 12 patients had undergone artificial respiration; 10 patients had invalid tissue materials; 4 patients showed AD, DLB, or AGD comorbidity; and 1 patient exhibited anoxic changes. They were further subclassified into FTD (n ¼ 14) and FTD-MND (n ¼ 17) groups. Among the 21 patients with pathologically confirmed ALS-TDP, 15 patients were placed in the ALS group, while 6 patients were excluded because 5 had undergone artificial respiration, and 1 patient had DLB. The median clinical duration times were significantly shorter in the FTD-MND and ALS groups than the FTD group (p < 0.001) (Table) . Among the patients in the FTD and FTD-MND groups, 64.3% (n ¼ 9 of 14) and 70.6% (n ¼ 12 of 17), respectively, presented with bvFTD at the initial disease stage. The other patients (5 and 5 patients from the FTD and FTD-MND groups, respectively) showed language disorders as the initial sign of FTD, although bvFTD cooccurred in 8 of the patients (3 and 5 patients from the FTD and FTD-MND groups, respectively) at advanced disease stages. All type B patients, but none of the type A and C patients, presented with the FTD-MND phenotype during the course of the disease.
Regression Analyses
Striatal VGLUT-1 densities significantly correlated to 2 parameters as follows; the clinical subgroups including FTD, FTD-MND, and nondemented ALS (ß ¼ 0.765, p ¼ 0.004 in the caudate head); and the pathological subtypes of FTLD-TDP including type A, B, and C (ß ¼ 0.759, p ¼ 0.003 in the caudate head; ß ¼ 0.836, p ¼ 0.001 in the putamen). Thus, we compared densities of VGLUT-1-positive axon terminals according to these parameters. In contrast, we did not detect strong correlations on the other parameters, including ages of death, sex, clinical durations, subtypes of dementia (bvFTD, PNFA, or SD), formalin fixation times, and postmortem delay to autopsies (Supplementary Data Fig. S2 ).
Comparisons of Axon Terminal Densities Among the Clinical Subgroups
The FTD, FTD-MND, and ALS groups demonstrated marked loss of VGLUT-1-positive axon terminals in the striatum with relatively spared synaptophysin immunostaining ( Figs. 1 and 2 ). In the quantification of VGLUT-1-positive axon terminals, the caudate head of the FTD and FTD-MND groups showed significantly lower values than that of the ALS group (p < 0.001) and normal controls (p < 0.001) (Fig. 3A) . In the putamen, the FTD, FTD-MND, and ALS groups demonstrated significantly lower values than the normal controls (p < 0.001 in the FTD and FTD-MND groups; p < 0.012 in the ALS group) (Fig. 3A) . In the FTD and FTD-MND groups, VGLUT-1-positive axon terminals were markedly depleted in both the caudate head and putamen (Fig. 3B) . By contrast, the ALS group showed a putamen-predominant involvement of VGLUT-1-positive terminals (p < 0.001) (Fig. 3B) . Depletion of synaptophysin-positive axon terminals was also significant in the FTD and FTD-MND groups (p < 0.012) but was much milder than that of VGLUT-1-positive ones (Fig. 3C) .
Comparisons of VGLUT-1-Positive Axon Terminal Densities Among FTLD-TDP Pathological Subtypes
In the caudate head, densities of VGLUT-1-positive axon terminals were significantly lower in the patients with FTLD-TDP type C than in those with type B (p < 0.01). In the putamen, the type C patients showed a significantly lower value than the type A and B patients did (p < 0.01) (Fig. 3D) .
TDP-43 Aggregations in VGLUT-1-Positive Axon Terminals
All FTD and FTD-MND patients and 60% (n ¼ 9 of 15) of the ALS patients exhibited pTDP-43-positive inclusions in the cytoplasm of the striatal neurons. They also displayed granular configurations of pTDP-43 in the surface of neurites or neuropil of the striatum (Fig. 4) . of a clinical duration as nondemented ALS) (Fig. 5A-C) . Granular aggregations of pTDP-43 were also observed within the neurites or cytoplasm of the medium spiny neurons, which were recognized using calcineurin (Fig. 5D-F) . This finding was observed in all patients that we subjected to the confocal microscopy.
DISCUSSION
The present study is the first to reveal loss of VGLUT-1-positive axon terminals in the striatum of FTLD-TDP and ALS-TDP patients. Our results indicated that FTLD-TDP and ALS-TDP are both characterized by a vulnerability of glutamatergic inputs to the striatum from the cortices. In comparisons between the clinical subgroups, the FTD and FTD-MND groups showed a more severe loss of VGLUT-1-positive axon terminals than the nondemented ALS group, particularly in the caudate head. This trend was clear even in a comparison between the clinical FTD-MND and ALS groups, in which the survival durations were comparably short. The clinicopathologic comparisons indicated that severe depletion of glutamatergic inputs to the striatum from the cortices, particularly those to the caudate head, may contribute to the sociocognitive declines in the disease spectrum of TDP-43 proteinopathy. Moreover, the patients with type C pathology tended to show more severe loss of VGLUT-1-positive axon terminals than those with other pathological subgroups did. This trend indicated that glutamatergic inputs to the striatum from the cortices are particularly vulnerable to FTLD-TDP type C.
Depletion of VGLUT-1-positive axon terminals could also arise from a reduced neuronal density in the striatum. However, we found no correlation between alterations in VGLUT-1 and synaptophysin expression using immunohistochemistry. There were clear differences in VGLUT-1 expression among the groups, but not in synaptophysin expression. According to these results, the loss of VGLUT-1-positive axon terminals indicated preferential involvement of glutamatergic cortico-striatal inputs and was not simply a reflection of general synaptic loss as a consequence of striatal neuron loss.
Using the tract-based spatial statistics method with MRI, we recently demonstrated significant depletion of frontal-caudate nucleus projections in clinical FTD-MND patients and ALS patients with mild cognitive decline compared with controls. Cognitively normal ALS patients were found to show mild but similar involvement based on probabilistic diffusion tractography (12) . These observations may be consistent with our pathologic results with respect to the correlation between impairment of cortico-caudate head projections and socio-cognitive decline in the ALS/FTD disease continuum. It is still unclear whether white matter pathology contributes to the disruption of cortico-striatal projections. Previous investigations have indicated that TDP-43 pathology often involves oligodendrocytes in the frontotemporal white matter (40) . In addition to cortical pathology, white matter pathology might be attributed to the degenerative processes of corticofugal axons and their terminals.
Our observations showed that pTDP-43 accumulated within VGLUT-1-positive axon terminals in the striatum of FTLD-TDP and ALS-TDP patients. This result indicated that aggregations of pTDP-43 may play some role in the destruction of VGLUT-1-positive terminals. Indeed, investigations using models involving TDP-43 overexpression have indicated neurotoxicity of insoluble pTDP-43 (41, 42) . Moreover, in AD patients, Ab-amyloid has been reported to accumulate within VGLUT-1-positive axon terminals in the cerebral cortex (43) . Recently, Braak et al proposed trans-axonal migration of TDP-43 inclusions and their propagation along neuroanatomic systems, starting at corticofugal neurons and extending to the subcortical efferent neurons in ALS patients (44, 45) . TDP-43 is primarily a nuclear protein, and the existence of pTDP-43 aggregations within VGLUT-1-positive terminals may be consistent with the trans-axonal spreading of TDP-43 proposed by this theory. Previously, we have reported pTDP-43 aggregations within the axon terminals of striatofugal neurons in patients with FTLD/ALS-TDP (31) . Considering our previous and present studies together, TDP-43 pathology seems to systematically involve the corticostriatal projection neurons and striatal efferent neurons along the neuroanatomy. However, it was notable that only a subset of our patients showed aggregations of pTDP-43 within VGLUT-1-positive axon terminals of the corticostriatal projection neurons. The colocalizations were less frequent than what was expected from remarkable and common depletion of VGLUT-1-positive axon terminals in our patients. Importantly, the propagation theory of Braak et al. also indicates that insoluble pTDP-43 granules occur in striatofugal axons but are hardly detectable in corticofugal axons. There might be additional pathways that destroy the axon terminals of cortico-striatal projection neurons, in addition to the in situ neurotoxicity of the accumulated pTDP-43.
The VGLUT family plays essential roles in the glutamatergic excitatory system via the vesicular accumulation of glutamate within presynaptic terminals. Several studies have revealed the relationships between the reduction of FIGURE 3. Quantitative immunohistochemistry results. In the caudate head, densities of VGLUT-1-immunostaining were significantly lower in the FTD and FTD-MND groups than the ALS group and normal control (A). In the putamen, the FTD, FTD-MND, and ALS groups showed significantly lower values than the normal control (A). In the ALS group, the putamen showed a more severe loss of VGLUT-1 immunostaining than the caudate head did (B). Loss of synaptophysin immunostaining was also significant in the patients but was much milder than that of VGLUT-1 immunostaining (C). Among pathological subtypes of FTLD-TDP, the type C patients tended to show more severe depletion of VGLUT-1 immunostaining than the other subtypes (D). Mann-Whitney U test. The significance level was set at a p value of 0.05 for comparisons between 2 groups, at a p value of 0.016 for comparisons among 3 groups, and at a p value of 0.012 for comparisons among 4 groups. *p < 0.012 and **p < 0.001 (A, C); #p < 0.01 (B); †p < 0.01 (D).
VGLUT-1-ergic axon terminals and socio-cognitive declines. A correlation of decreased striatal VGLUT-1 levels and executive dysfunctions has been described in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced models of PD (46) . Experiments using VGLUT-1-heterozygous mice with globally reduced VGLUT-1 expression have shown significant executive disorders in learning tasks or abnormal behaviors (47, 48 ). An autopsy study of vascular dementia showed that low concentrations of VGLUT-1 in the prefrontal cortices were correlated with more severe cognitive declines (49). Experimental or postmortem investigations in AD have also revealed specific vulnerability of glutamatergic terminals of the hippocampus or cerebral neocortices (50, 51) . It is well established that glutamatergic cortico-striatal projections are important for execution, verbal generation, and mood regulation (19) (20) (21) . Importantly, depletion of glutamatergic inputs to the striatum from the cortices may also be a potential pathway of socio-cognitive manifestations in FTLD-TDP.
Our investigation presented 3 methodologic limitations. First, it was difficult to immunohistochemically label the perikarya of cortico-striatal projection neurons. Peptidergic expression of VGLUT-1 is strongly limited to the axon terminals, and other peptidergic markers specific to the cellular bodies of the cortico-striatal projection neurons have not yet been established (22) (23) (24) . This issue must be overcome to pathologically evaluate the cortico-striatal projection neurons at the cortical level. Second, we did not detect any differences in the severity or pattern of the loss of VGLUT-1-ergic axon terminals among the clinical subtypes of FTD, including bvFTD and language disorders. This issue needs to be further investigated, due to the relatively small number of patients with language disorders and the high prevalence of comorbid language and behavioral disorders at advanced disease stages in our patient series. Third, diversity of postmortem delay or formalin fixation time was inevitable for autopsy materials. These durations may effect protein preservation in the brain tissues (52) . However, in our study, the clinical or pathological phenotypes more correlated to VGLUT-1 immunostaining than these methodological parameters. Moreover, as shown in Figure 1 , VGLUT-1 immunostaining of the patients was prominently diminished in the striatum with relatively spared immunostaining in the insula or claustrum. These findings suggest that depletion of VGLUT-1 immunostaining we observed was pathologic but not consequence of nonspecific protein loss associated with postmortem artifacts.
In conclusion, we elucidated the pathologic changes in VGLUT-1-positive axon terminals in FTLD-TDP and ALS-TDP patients. Our results indicated preferential involvement of glutamatergic inputs to the striatum from the cerebral cortices in FTLD/ALS-TDP patients and its contribution to cognitive decline in a disease spectrum of TDP-43 proteinopathy. However, further investigation is needed to clarify the molecular mechanisms underlying the impairment of the VGLUT-1-positive axon terminals.
